BRAF and melanoma: Metastatic melanoma patients have a bad prognosis and only a limited number of therapy alternatives are available.1 Therefore, discovering oncogenic BRAF in most melanomas (80% cases) and showing that BRAF mutant melanoma cells rely heavily on BRAF/MAPK signaling were significant findings with substantial pharmacological impact.